

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT IN RELATION TO SERIES A FINANCING OF THE COMPANY'S PARTNER SOLSTICE ONCOLOGY

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, Solstice Oncology (“**Solstice**”), the Company’s partner company, has launched with a US\$225 million Series A financing round led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.

Solstice is a clinical-stage immuno-oncology company focused on treating cancer earlier, in the neoadjuvant setting. Solstice is advancing its lead candidate porustobart, a differentiated, second-generation, Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (“**CTLA-4**”) antibody, across two clinical indications, one in microsatellite-stable (“**MSS**”) colon cancer and a second, undisclosed indication. Its Phase 2 trial is evaluating porustobart in combination with pembrolizumab in the neoadjuvant setting for the treatment of MSS clinical stage II-III colon cancer, the indication with the largest segment of colon cancer patients, which has yet to benefit from immunotherapy. The Phase 2 trial is expected to be open for enrollment early in the fourth quarter of 2026, with data anticipated in the second half of 2027.

ABOUT SOLSTICE ONCOLOGY

Solstice Oncology is a clinical-stage immuno-oncology company built around the neoadjuvant treatment setting, the point in a patient’s disease course where the company believes the opportunity to improve cure rates and long-term survival is greatest. Founded in February 2026, Solstice is led by a team with decades of experience building and advancing successful immunotherapy drugs in oncology. The company is advancing porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, across two clinical indications: a Phase 2 study in combination with pembrolizumab in the neoadjuvant setting for clinical stage II-III MSS colon cancer, and a second, undisclosed clinical indication. Solstice’s initial investors include RA Capital Management, Canaan Partners and Forbion.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang

Chairman and Executive Director

Hong Kong, 9 September 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.